Medivir AB (publ) – LSE:0GP7.L

Medivir AB (publ) stock price today

SEK 41.7
+38.90
+1389.29%
Financial Health
0
1
2
3
4
5
6
7
8
9

Medivir AB (publ) stock price monthly change

-21.57%
month

Medivir AB (publ) stock price quarterly change

-21.57%
quarter

Medivir AB (publ) stock price yearly change

-61.91%
year

Medivir AB (publ) key metrics

Market Cap
 313.74M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -1.39
Revenue
 5.80M
EBITDA
 -77.96M
Income
 -76.99M
Revenue Q/Q
 300%
Revenue Y/Y
 -60.20%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -1342.39%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Medivir AB (publ) stock price history

Medivir AB (publ) stock forecast

Medivir AB (publ) financial statements

Profit Margin

Medivir AB (publ) (LSE:0GP7.L): Profit margin
Sep 2022 1.1M -15M -1363.64%
Dec 2022 2.30M -17.09M -740.6%
Mar 2023 400K -18.3M -4575%
Jun 2023 2M -26.6M -1330%
0GP7.L income statement history

Medivir AB (publ) Financials Estimate

Medivir AB (publ) (LSE:0GP7.L): Analyst Estimates
2025 69.56M -77.32M -111.15%
2026 13.8M -82.56M -598.28%
2027 239.36M -16.34M -6.83%
2028 660.04M 104.03M 15.76%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Medivir AB (publ) (LSE:0GP7.L): Debt to assets
Sep 2022 259300000 48.8M 18.82%
Dec 2022 234197000 41.40M 17.68%
Mar 2023 216200000 42.3M 19.57%
Jun 2023 199800000 51.9M 25.98%
0GP7.L balance sheet history

Cash Flow

Medivir AB (publ) (LSE:0GP7.L): Cash Flow
Sep 2022 -19.7M -400K -500K
Dec 2022 -24.72M 18K -135K
Mar 2023 -16.1M 0 -500K
Jun 2023 -17.9M -300K 200K
0GP7.L cash flow history

Medivir AB (publ) alternative data

Medivir AB (publ)
Employees

Medivir AB (publ) (LSE:0GP7.L): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 9
Dec 2023 10
Jan 2024 10
Feb 2024 10
Mar 2024 10
Apr 2024 10
May 2024 10
Jun 2024 10
Jul 2024 10

Medivir AB (publ) other data

Frequently Asked Questions (FAQ)

  • What's the price of Medivir AB (publ) stock today?

    One share of Medivir AB (publ) stock can currently be purchased for approximately $41.7.

  • When is Medivir AB (publ)'s next earnings date?

    Unfortunately, Medivir AB (publ)'s (0GP7.L) next earnings date is currently unknown.

  • Does Medivir AB (publ) pay dividends?

    No, Medivir AB (publ) does not pay dividends.

  • How much money does Medivir AB (publ) make?

    Medivir AB (publ) has a market capitalization of 313.74M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 82.74% to 4.41M US dollars.

  • What is Medivir AB (publ)'s stock symbol?

    Medivir AB (publ) is traded on the LSE under the ticker symbol "0GP7.L".

  • What is Medivir AB (publ)'s primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Medivir AB (publ)?

    Shares of Medivir AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Medivir AB (publ) have?

    As Jul 2024, Medivir AB (publ) employs 10 workers.

  • When Medivir AB (publ) went public?

    Medivir AB (publ) is publicly traded company for more then 2 years since IPO on 7 Jun 2023.

  • What is Medivir AB (publ)'s official website?

    The official website for Medivir AB (publ) is medivir.com.

  • How can i contact Medivir AB (publ)?

    Medivir AB (publ) can be reached via phone at +46 8 546 831 00.

Medivir AB (publ) company profile:

Medivir AB (publ)

medivir.com
Exchange:

LSE

Full time employees:

10

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

+46 8 546 831 00
Lunastigen 5
Huddinge,

:
ISIN: SE0020181014
CUSIP: W56151108